RJA
RGNX icon

Raymond James & Associates’s Regenxbio RGNX Stock Holding History

Raymond James & Associates’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$344K Sell
32,809
-4,416
-12% -$53.8K ﹤0.01% 3329
2024
Q2 		$436K Sell
37,225
-17,924
-33% -$279K ﹤0.01% 3152
2024
Q1 		$1.16M Buy
55,149
+4,612
+9% +$82.1K ﹤0.01% 2503
2023
Q4 		$907K Sell
50,537
-50,083
-50% -$882K ﹤0.01% 2573
2023
Q3 		$1.66M Buy
100,620
+80,706
+405% +$1.46M ﹤0.01% 2130
2023
Q2 		$398K Buy
19,914
+3,083
+18% +$59.4K ﹤0.01% 3074
2023
Q1 		$318K Buy
16,831
+3,130
+23% +$69.3K ﹤0.01% 3201
2022
Q4 		$311K Buy
13,701
+4,898
+56% +$111K ﹤0.01% 3193
2022
Q3 		$233K Sell
8,803
-11,880
-57% -$352K ﹤0.01% 3347
2022
Q2 		$511K Buy
20,683
+3,100
+18% +$77.4K ﹤0.01% 2902
2022
Q1 		$584K Sell
17,583
-3,240
-16% -$90K ﹤0.01% 2973
2021
Q4 		$681K Sell
20,823
-9,894
-32% -$337K ﹤0.01% 2874
2021
Q3 		$1.29M Sell
30,717
-15,444
-33% -$556K ﹤0.01% 2408
2021
Q2 		$1.79M Buy
46,161
+1,721
+4% +$61.6K ﹤0.01% 2170
2021
Q1 		$1.52M Buy
44,440
+19,625
+79% +$837K ﹤0.01% 2215
2020
Q4 		$1.13M Sell
24,815
-2,055
-8% -$71.8K ﹤0.01% 2263
2020
Q3 		$739K Sell
26,870
-1,435
-5% -$46.8K ﹤0.01% 2366
2020
Q2 		$1.04M Buy
28,305
+2,494
+10% +$93K ﹤0.01% 2138
2020
Q1 		$836K Sell
25,811
-1,960
-7% -$81.7K ﹤0.01% 2103
2019
Q4 		$1.14M Sell
27,771
-1,593
-5% -$62.9K ﹤0.01% 2193
2019
Q3 		$1.04M Buy
29,364
+2,349
+9% +$95.2K ﹤0.01% 2182
2019
Q2 		$1.39M Sell
27,015
-10,937
-29% -$546K ﹤0.01% 2023
2019
Q1 		$2.17M Buy
37,952
+20,664
+120% +$1.02M ﹤0.01% 1708
2018
Q4 		$725K Sell
17,288
-950
-5% -$55.7K ﹤0.01% 2295
2018
Q3 		$1.38M Sell
18,238
-4,255
-19% -$307K ﹤0.01% 2039
2018
Q2 		$1.61M Buy
+22,493
New +$1.07M ﹤0.01% 1902

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Raymond James & Associates's RGNX Position: Q3 2024 in Review

Raymond James & Associates reduced its Regenxbio (RGNX) stake by 12% in Q3 2024, selling an estimated $53.8K and leaving 32,809 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #3329.

Raymond James & Associates first reported a position in RGNX in Q2 2018 and has held it in 26 quarters since. The position peaked at $2.17M in Q1 2019. 186 funds tracked by Wall St. Rank hold RGNX as of Q3 2024.

  • Raymond James & Associates held 32,809 shares of Regenxbio worth $344K as of Q3 2024.
  • Raymond James & Associates sold 4,416 Regenxbio shares in Q3 2024, an estimated $53.8K.
  • Regenxbio made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3329 holding.
  • Raymond James & Associates first reported a position in Regenxbio in Q2 2018 and has held it in 26 quarters since.
  • Raymond James & Associates's Regenxbio position peaked at $2.17M in Q1 2019.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.